According to the recent research report titled ‘Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027’, available with Market Study Report, global anticoagulants market is expected to accrue substantial revenues over 2021-2027.
 

Global anticoagulants market growth is primarily driven by booming elderly population, along with prevalence of chronic diseases, and increasing acceptance of novel oral anticoagulants (NOACs).
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3692084/
 

For the unversed, anticoagulants are medications that aid in the prevention of blood clotting. These are offered to patients who are at a higher risk of blood clots, as well as to reduce the risk of catastrophic health conditions such as heart attacks and strokes.
 

Speaking of challenges, strict regulatory framework, and high risk of side effects related to anticoagulants are anticipated to negatively impact the industry expansion.
 

Considering drug class, warfarin segment held 1.8% of overall market share in 2020 and is expected to gain traction over 2021-2027. Vitamin K antagonists (warfarin) work by preventing the liver from converting vitamin K into components that aid in blood coagulation. This also helps to keep blood clotting under control. One of the most significant advantages of this anticoagulant drug class is that it is easier to reverse than other types in the event of unexpected bleeding following an emergency or trauma surgery.
 

Elaborating on route of administration, global anticoagulants market share from oral segment was worth USD 14.2 billion in 2020 and is projected to grow substantially over the ensuing years.
 

As per application spectrum, atrial fibrillation/flutter segment is projected to be valued at USD 14.1 billion by the year 2027. Anticoagulants or blood thinning drugs are prescribed to reduce the risk of stroke among individuals with atrial fibrillation who are at a higher risk of thromboembolism or stroke from blocked arteries.
 

Based on distribution channel, hospital pharmacy segment is anticipated to grow with a CAGR of 6% during the assessment period.
 

Regionally, Latin America held 1.3% share in overall anticoagulants industry in 2020 and is expected to expand further through 2027. Meanwhile, Middle East & Africa market amassed revenues worth USD 372.6 million in 2020 and is predicted to depict a similar growth pattern in the coming years.
 

Prominent firms operating in worldwide anticoagulants marketplace are Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Sanofi S.A., Laboratorios Farmacéuticos ROVI, Pfizer Inc., United Therapeutics Corporation, Leo Pharma A/S, Amphastar Pharmaceuticals Inc., Portola Pharmaceuticals Inc., Daiichi Sankyo Company, Johnson & Johnson, Boehringer Ingelheim, Bayer AG, and Bristol-Myers Squibb Company.